Intarcia Therapeutics

BioTech | Funding to Date: $961,464,514

Intarcia Therapeutics is a biopharmaceutical company developing therapies to enhance treatment outcomes by optimizing and improving the efficacy, continuous administration, and tolerability of drug therapies for diseases that require long-term chronic treatment. Intarcia is currently conducting a three-stage development program for Type 2 diabetes that consist of four separate clinical trials, two of which have been successfully completed. Intarcia also continues to conduct research and development to treat other chronic serious disorders in the field of diabetes and obesity.